Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance

2021 ◽  
Author(s):  
M. Murali ◽  
A. R. Kumar ◽  
B. Nair ◽  
K. Pavithran ◽  
A. R. Devan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Relevance ◽  
Preclinical Studies ◽  
Targeted Therapeutics ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

Abstract 5618: Anti-FGFR4 antibody drug conjugate for immune therapy of rhabdomyosarcoma and hepatocellular carcinoma

2018 ◽  
Author(s):  
Adam Cheuk ◽  
Nitya Shivaprasad ◽  
Martin Skarzynski ◽  
Sivasubramanian Baskar ◽  
Peter Azorsa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune Therapy ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

Abstract 50: Targeting Sialyl-Thomsen nouveau (STn) antigen with the SGN-STNV antibody-drug conjugate is effective in preclinical studies

2021 ◽  
Author(s):  
Alyssa Schwartz ◽  
Hector Rincon ◽  
Nanna Hansen ◽  
Robert Lawrence ◽  
Sarah Anderson ◽  
...  
Keyword(s):  
Preclinical Studies ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

mAbs ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 405-413 ◽  
Author(s):  
Yun Yang ◽  
Qingcheng Guo ◽  
Xi Chen ◽  
Junjie Zhang ◽  
Huaizu Guo ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
Preclinical Studies ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document